Core Insights - Cue Biopharma, Inc. has appointed Lucinda Warren as Chief Business Officer to enhance corporate development initiatives following a recent business restructuring and prioritization of autoimmune programs [1][2][3] Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics that selectively engage and modulate disease-specific T cells [4] - The company's proprietary platform, Immuno-STAT™, aims to harness the body's immune system for targeted therapeutic effects without broad systemic immune modulation [4] Leadership and Experience - Lucinda Warren brings over 30 years of experience in the pharmaceutical and biotechnology sectors, having held significant roles at Johnson & Johnson and Janssen [2][3] - Her most recent position was Vice President of Business Development for Neuroscience and Japan Region at Johnson & Johnson, where she managed end-to-end business development including licensing and mergers [3] - Warren's leadership has been pivotal in optimizing resources and fostering high-performing teams, contributing to successful strategic transactions [3] Strategic Focus - The company aims to align with third-party partnerships and collaborations to develop its immunotherapy platform, with a commitment to maximizing value for shareholders and patients [3] - Warren's appointment is seen as a strategic move to enhance the company's ability to capitalize on opportunities in a timely manner [3]
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer